E3 PreliminaryPreliminaryPEM unclearObservationalPeer-reviewedMachine draft
Polymorphisms in genes regulating the HPA axis associated with empirically delineated classes of unexplained chronic fatigue.
Smith, Alicia K, White, Peter D, Aslakson, Eric et al. · Pharmacogenomics · 2006 · DOI
Quick Summary
This study looked at whether different genetic variations in the stress-response system (HPA axis) and mood-related brain chemistry might explain why ME/CFS affects people differently. Researchers identified five distinct subgroups of people with chronic fatigue and found that three of these groups had different versions of specific genes compared to healthy people, suggesting that ME/CFS may not be one disease but rather several different conditions with different underlying genetic causes.
Why It Matters
This research demonstrates that ME/CFS is not monolithic and that different patients may have different genetic underpinnings for their illness. Understanding these genetic subtypes could lead to personalized diagnosis and treatment approaches, rather than applying one-size-fits-all interventions to a heterogeneous population.
Observed Findings
- Five distinct latent classes of fatigued subjects were empirically delineated from a population-based sample.
- Three of the five ill classes showed significant gene polymorphism associations compared to the well class.
- Polymorphisms in HPA axis genes (POMC, NR3C1) and monoamine genes (MAOA, MAOB, TPH2) distinguished specific ill classes.
- Different ill classes were associated with different sets of genetic variants, suggesting mechanistic heterogeneity.
- Class 2 (well subjects, n=35) served as the comparator group across analyses.
Inferred Conclusions
- Medically unexplained chronic fatigue is genetically heterogeneous, with at least three distinct subtypes identifiable by HPA axis and neurotransmitter gene variants.
- Genetic differences in stress response and mood regulation systems may underlie clinically distinguishable subgroups within the fatigued population.
- This genetic heterogeneity may explain why ME/CFS presents with variable symptom profiles and treatment responses across patients.
Remaining Questions
- Do these genetic polymorphisms remain stable over time or change with disease progression and recovery?
- What are the functional consequences of these specific polymorphisms on protein expression and HPA axis physiology in ME/CFS patients?
What This Study Does Not Prove
This study does not prove that these genetic polymorphisms cause ME/CFS—it only shows associations in this particular sample. The cross-sectional design cannot establish causality, and the findings require replication in larger, independent populations before conclusions about genetic causation can be drawn.
Tags
Symptom:Fatigue
Biomarker:Gene Expression
Method Flag:Weak Case DefinitionSmall SampleExploratory OnlyMixed Cohort
Metadata
- DOI
- 10.2217/14622416.7.3.387
- PMID
- 16610949
- Review status
- Machine draft
- Evidence level
- Early hypothesis, preprint, editorial, or weak support
- Last updated
- 8 April 2026
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →